Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
Launched by CHULALONGKORN UNIVERSITY · Sep 18, 2017
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Elevated protein-bound toxins including p-cresol (pCS) and indoxyl sulfate (IDS) as well as middle-molecular toxins such as beta2-microglobulin (B2M) which could not be removed by hemodialysis (HD) are obviously correlated with high mortality. High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance pCS, IDS, and B2M removal and improve patient survival. Unfortunately, the majority of patients could not reach that high BF because of vascular access issue. We innovated the OL-HDF ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • End-stage renal disease patients treated with thrice-a-week OL-HDF for at least 6 months
- • Residual urine \< 100 mL/day
- Exclusion Criteria:
- • Active cardiovascular disease
- • Active malignancy
- • Pregnancy
- • Breast-feeding
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Khajohn Tiranathanagul, MD
Principal Investigator
Chulalongkorn University
Wanjak Pongsittisak
Principal Investigator
Chulalongkorn University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials